{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:55:11Z","timestamp":1781373311140,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myasthenia gravis is an autoimmune disorder characterized by antibodies targeting the neuromuscular junction, causing fatigue of skeletal muscle. Natural history and epidemiological studies report that around 10% of patients diagnosed with myasthenia gravis do not have detectable levels of antibodies, categorized as seronegative. Theories of the pathophysiology in these patients are predominantly centered around undetectable antibody titers and antibodies against yet undefined antigens in the neuromuscular junction. This study aims to investigate the regional prevalence and characteristics of patients with seronegative myasthenia gravis. This study is a retrospective chart review of 350 patients with myasthenia gravis treated at the Copenhagen Neuromuscular Center. Of these, 15 (4.3%) were seronegative and 335 (95.7%) were seropositive. No differences were found when comparing the two groups on demographics, symptom profile, comorbidities, treatment, and diagnostic delay. The frequency of seronegative myasthenia gravis patients was lower in this cohort than previously reported. Seronegative myasthenia gravis patients were essentially indistinguishable from seropositive patients on all parameters evaluated. These findings correspond well with the emerging evidence of a similar pathophysiology in the two groups.<\/jats:p>","DOI":"10.1007\/s00415-026-13837-7","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:27:27Z","timestamp":1778336847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and characteristics of patients with seronegative myasthenia gravis"],"prefix":"10.1007","volume":"273","author":[{"given":"Rebecca Kj\u00e6r","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5384-6825","authenticated-orcid":false,"given":"Peter","family":"Ankj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper Holst","family":"Axelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Kahr","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna","family":"Witting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"13837_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12:259\u2013268. https:\/\/doi.org\/10.1038\/nrneurol.2016.44","journal-title":"Nat Rev Neurol"},{"key":"13837_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","volume":"2","author":"A Vincent","year":"2002","unstructured":"Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797\u2013804. https:\/\/doi.org\/10.1038\/nri916","journal-title":"Nat Rev Immunol"},{"key":"13837_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"key":"13837_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475\u2013490. https:\/\/doi.org\/10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"13837_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","volume":"69","author":"B Zhang","year":"2012","unstructured":"Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69:445\u2013451. https:\/\/doi.org\/10.1001\/archneurol.2011.2393","journal-title":"Arch Neurol"},{"key":"13837_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","volume":"292","author":"C Stergiou","year":"2016","unstructured":"Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C et al (2016) Titin antibodies in \u201cseronegative\u201d myasthenia gravis--a new role for an old antigen. J Neuroimmunol 292:108\u2013115. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.01.018","journal-title":"J Neuroimmunol"},{"key":"13837_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R et al (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139\u2013145. https:\/\/doi.org\/10.1016\/j.jaut.2013.12.004","journal-title":"J Autoimmun"},{"key":"13837_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13091286","volume":"13","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Lupica A, Ginanneschi F, Piscosquito G, Rini N et al (2023) Diagnosis and management of seronegative myasthenia gravis: lights and shadows. Brain Sci 13:1286. https:\/\/doi.org\/10.3390\/brainsci13091286","journal-title":"Brain Sci"},{"key":"13837_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ (2020) Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol 11:596981. https:\/\/doi.org\/10.3389\/fneur.2020.596981","journal-title":"Front Neurol"},{"key":"13837_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","volume":"12","author":"JJGM Verschuuren","year":"2013","unstructured":"Verschuuren JJGM, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P et al (2013) Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 12:918\u2013923. https:\/\/doi.org\/10.1016\/j.autrev.2013.03.001","journal-title":"Autoimmun Rev"},{"key":"13837_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A, Nowak RJ, O\u2019Connor KC (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776. https:\/\/doi.org\/10.3389\/fimmu.2020.00776","journal-title":"Front Immunol"},{"key":"13837_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","volume":"264","author":"I Cordts","year":"2017","unstructured":"Cordts I, Bodart N, Hartmann K, Karagiorgou K, Tzartos JS, Mei L et al (2017) Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. J Neurol 264:1193\u20131203. https:\/\/doi.org\/10.1007\/s00415-017-8514-z","journal-title":"J Neurol"},{"key":"13837_CR13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"13837_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A et al (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375:511\u2013522. https:\/\/doi.org\/10.1056\/NEJMoa1602489","journal-title":"N Engl J Med"},{"key":"13837_CR15","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP et al (2008) IgG1 antibodies to acetylcholine receptors in \u201cseronegative\u201d myasthenia gravis. Brain 131:1940\u20131952. https:\/\/doi.org\/10.1093\/brain\/awn092","journal-title":"Brain"},{"key":"13837_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","volume":"72","author":"PM Rodr\u00edguez Cruz","year":"2015","unstructured":"Rodr\u00edguez Cruz PM, Al-Hajjar M, Huda S, Jacobson L, Woodhall M, Jayawant S et al (2015) Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol 72:642\u2013649. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0203","journal-title":"JAMA Neurol"},{"key":"13837_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1055\/s-2004-829589","volume":"24","author":"A Vincent","year":"2004","unstructured":"Vincent A, McConville J, Farrugia ME, Newsom-Davis J (2004) Seronegative myasthenia gravis. Semin Neurol 24:125\u2013133. https:\/\/doi.org\/10.1055\/s-2004-829589","journal-title":"Semin Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13837-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:09:24Z","timestamp":1781370564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13837-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["13837"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13837-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors: Research funded partly by UCB. John Vissing: Consultant on advisory boards for Roche, Regeneron, Argenx BVBA, UCB Biopharma SPRL, and Horizon Therapeutics. Research, travel support, and\/or speaker honoraria from Alexion Pharmaceuticals and UCB Biopharma SPRL. Nanna Witting: Study grant from UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"308"}}